86 filings
8-K
BRNS
Barinthus Biotherapeutics Plc.
18 Apr 24
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
4:15pm
ARS
2023 FY
BRNS
Barinthus Biotherapeutics Plc.
22 Mar 24
Annual report to shareholders
8:43am
DEFA14A
BRNS
Barinthus Biotherapeutics Plc.
22 Mar 24
Additional proxy soliciting materials
8:41am
DEF 14A
BRNS
Barinthus Biotherapeutics Plc.
Definitive proxy
22 Mar 24
8:36am
S-8
BRNS
Barinthus Biotherapeutics Plc.
20 Mar 24
Registration of securities for employees
5:02pm
8-K
5y8jh53qlx1zeo k7
20 Mar 24
Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments
8:24am
8-K
4hrdgg50b3dhtaw r70d
5 Jan 24
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
4:15pm
8-K
jbe640n63zk8b4
22 Dec 23
New partnership aims to advance vaccine against MERS coronavirus
4:01pm
8-K
6hfsj yps27d
9 Nov 23
Regulation FD Disclosure
4:32pm
8-K
nhlvx ho4z5j2ke
9 Nov 23
Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
4:10pm
8-K
aj1tuyeqcm
6 Nov 23
Submission of Matters to a Vote of Security Holders
11:04am
PRE 14A
44701c1o ithj
25 Sep 23
Preliminary proxy
5:19pm
8-K
zhgb6i
10 Aug 23
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
8:12am
8-K
vqw3qfmu
26 Jul 23
Departure of Directors or Certain Officers
4:06pm
8-K
g2cvpr
21 Jun 23
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
4:05pm